Autopsy report · NCT02008539

Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

“Enrollment terminated after 13 patients (14 planned); further patients did not meet eligibility criteria to receive autologous IMP”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 11 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Apceth GmbH & Co. KG

Sponsor type

Industry

Conditions

Advanced Gastrointestinal Cancer

Interventions

MSC_apceth_101

Participants

13

Sites

1

Countries

Germany

Trials that died the same way

• Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity
  “terminated after 2 patients due to difficulty in enrollment” (65% match in meaning)
• Alvimopan Use in Polytraumatized Patients
  “This study was terminated due to failure to enroll, a low volume of patients met criteria.” (63% match in meaning)
• Digital Therapeutic vs Educational App for Depression Among Adolescents
  “Terminated due to difficulty enrolling patients in the proposed time frame” (63% match in meaning)
• Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
  “enrollment halted in order to have all patients complete follow-up by Jan 2011” (62% match in meaning)
• Daytime Impact Sleep Study
  “Terminated due to lack of eligible patients” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.